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Background: Given the importance of patient safety and well-being, we quantified the likelihood and
type of medication changes observed after 5 possible adverse effects (AE) perceived by heart failure
(HF) patients.
Methods and Results: We conducted a retrospective cohort study using 18 months follow-up data from
the Coordinating study evaluating Outcomes of Advising and Counseling in HF study on 754 patients pre-
viously hospitalized for HF (NYHA II-IV, mean age 70 years). Data used for this secondary analysis in-
cluded problem checklists that patients had completed at 3 points in time, and medication data collected
from chart review. Changes in potential causal cardiovascular medication and relevant alleviating medi-
cation were classified. Within group and relative risks (RR) for medication changes were calculated. Of
the 754 patients, 50% reported dizziness, 44% dry cough, 19% nausea, 19% diarrhea, and 12% gout on
the first checklist. Overall, the likelihood of a medication change was increased by 38% after a perceived
AE. Dry cough had the highest increased likelihood of an associated cardiovascular medication change
(RR 1.83, CI 1.35-2.49). Patients reporting gout had a four fold higher likelihood of alleviating medication
started or intensified.
Conclusions: A considerable number of HF patients perceived possible AE. However, the likelihood of
medication being changed after a possible AE was rather low. There seems to be room for improving the
management of AE. (J Cardiac Fail 2010;16:135e143)
Key Words: Cardiovascular disease, adverse drug reactions, risk management, physician-patient relations.Pharmacological treatment is the cornerstone of heart
failure (HF) management, significantly improving morbid-
ity and mortality.1,2 Although medication is in general ben-
eficial, it has the potential to do harm as well. We
previously reported that up to 17% of HF patients may ex-
perience (mild) adverse effects of their medication.3 When
patients raise concerns about possible adverse effects, phy-
sicians may not actively engage in the discussion, and pa-
tients’ concerns are not always identified.4 This may
affect the quality of life and patient adherence and increaseartments of Clinical Pharmacology; 2Cardiology and
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135patients’ dissatisfaction with care.5-7 In addition, the failure
to respond to medication related symptoms can also con-
tribute to unnecessary discomfort and harm caused by
ameliorable adverse drug events.8,9 The severity or the
duration of such events could be reduced by adequate
(re)action.5
So far, little information is available about the extent of
adequate reaction to possible adverse effects in HF patients.
Information about medication changes to stop or ameliorate
adverse events is helpful to identify aspects of management
in need of improvement.
The objective of this study was to evaluate the impact of
perceived adverse effects that can be caused by drugs
frequently used in HF patients on the
- likelihood and type of changes of potential causal
cardiovascular medication and
- initiation of medication to alleviate the adverse effect.
Methods
Sample and Setting
The current study used secondary data which had been collected
in a multicenter randomized controlled trial, the Coordinating
Box 1. Definitions of Medication Changes
Medication changes related to causal cardiovascular drugs:
Stop: A medication is considered to be stopped when it is
discontinued and not restarted in a maximum period of 6 months
(between 2 problem checklists).
Gap: There is a discontinuation in the prescribed medication
ranging from a minimum of 2 days to a maximum of 6 months,
depending on the dosage at reinitiating (ie, gap with lower dosage
or a gap with the same dosage).
Switch: A new drug is started within 2 days after medication is
discontinued. Switching of medication can occur at different
levels of the ATC classification for drug treatment. Switch at level
5: a switch between two drugs at the chemical substance level (eg,
lisinopril-perindopril).
Switch at level 4: a switch between two drugs at the chemical
subgroup level (eg, thiazide-thiazide combination product).
Switch at level 3: a switch between two drugs within the same
pharmacological subgroup (eg, ACE-inhibitor to ARB).
Dose decrease: A decrease in the dosage of the same medication.
Medication changes related to alleviating drugs:
Start: A medication is considered to be started when it was not
prescribed in a maximum period of 6 months (between 2 problem
checklists).
Gap: Conform the Gap definition above, except focusing at a gap
with a higher dosage at reinitiation.
Switch: Conform the Switch definition above.
Dose increase: An increase in the dosage of the same medication.
ATC: Anatomical Therapeutic Chemical (ATC); ACE inhibitor:
angiotensin-converting enzyme inhibitor; ARB: angiotensin
receptor blocker.
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COACH study).10,11 The COACH study was designed to deter-
mine the effect of education and counseling in HF patients. All pa-
tients were enrolled in the study between October 2002 and
February 2005 when they were hospitalized for symptomatic HF
(New York Heart Association functional Class [NYHA] II-IV)
in 1 of 17 heart failure clinics spread over the Netherlands. To
be included, patients needed to be older than 18 years and had
to have evidence of structural underlying heart disease. Exclusion
criteria were invasive procedures in the months before or planned
within 3 months after the baseline, already enrolled in other stud-
ies, follow-up treatment at another HF clinic, unable or unwilling
to complete questionnaires, or to give informed consent. After giv-
ing written informed consent in the COACH study, patients were
randomized at discharge (baseline) to either care as usual or to 2
intervention care groups: a basic support group or an intensive
support group.
Study Design and Data Collection
We conducted a retrospective cohort study using 18-month fol-
low-up data from the COACH study. For this secondary analysis,
we used information from medical charts and questionnaires that
patients had completed at month 1, 6, and 12 after discharge
from the hospital. The Central Ethics Committee approved the
study and the investigation conformed to the principles outlined
in the Declaration of Helsinki.
Measures
Perceived Adverse Drug Effects. A checklist of 15 disease-
or drug-related symptoms or problems that are often perceived by
HF patients was used to collect data on possible adverse effects.
The question was phrased as follows: ‘‘Did you experience sincethe last interview:?’’ (list of 15 problems) (yes or no). Of the prob-
lems addressed, 5 were possible adverse effects of cardiovascular
medication that could be consistently related to pharmacological
subgroups of such drugs (see the following section). These were
included in our study, and concerned dry or hacking cough (5
dry cough), nausea, dizziness, diarrhea, and gout. To separate
cough associated with worsening HF from the dry or hacking
cough caused by angiotensin-converting enzyme (ACE) inhibitors,
coughing in general was not included in our analysis, though it
was included as a separate problem in the checklist.
Medication Therapy. All prescribed medication and medica-
tion changes were registered during 18 months of follow-up in the
electronic patients’ charts. We classified medication changes into
different types of changes that could be considered as indicated re-
actions to the perceived adverse drug effects (Box 1). As potential
causal drugs, we included all cardiovascular medications (C-group
within the Anatomical Therapeutic Chemical classification sys-
tem), which were prescribed at least once in the included patient
cohort (21 drugs). Medications were considered related to 1 or
more of the possible adverse effects when that specific adverse ef-
fect was mentioned as a pharmacological subgroup effect in the
Drug Compendium (Appendix 1).12 For example, dry cough was
considered to be related to ACE inhibitors, whereas dizziness
could be related to 18 different subgroups, such as cardiac glyco-
sides, antiarrhythmics (class I and III), or b-blockers. For each of
the 5 adverse effects, alleviating medication was defined as any
drug that was indicated for that specific problem according to
the Drug Compendium (Appendix 1). For example, both nonste-
roidal anti-inflammatory drugs (M01A) and antigout preparations
(M04A) have gout as an indication, and were therefore included in
the analysis.
Demographic and Clinical Variables
Demographic and clinical variables were collected from patient
interviews administered at discharge and from the medical charts.
Statistical Analysis
We performed descriptive analysis to calculate the number of
perceived possible adverse effects, the percentages of such adverse
effects that could be related to concurrently prescribed medica-
tion, and related medication changes in the following period of
5 to 6 months. In this way, we limited the period between the per-
ceived problem and the action taken to a maximum of 6 months.
Each patient had a maximum of 3 occasions to report a possible
adverse effect. Patients who perceived a specific adverse effect
were included up to their first report. A separate descriptive
analysis was conducted for patients who reported the same
adverse effect on all 3 occasions.
We estimated the likelihood of receiving a related medication
change in the period after a positive or a negative report of a pos-
sible adverse effect by calculating the within group risk (R) and
the relative risk (RR) with 95% confidence intervals (CI).
First, we calculated the overall likelihood of receiving a medica-
tion change after a perceived adverse effect. For this, we compared
patients with and without any report of an adverse effect in the
first period regarding all related medication changes. To assess
whether medication changes were more likely for HF-specific
medication, we performed subanalyses for HF-specific and other
cardiovascular medications, including the adverse effects that
could be attributed to both groups of medication. Ratio of relative
risks (RRR) and test of interaction (z-score) were calculated to
Table 1. Demographic and Clinical Characteristics of the
HF Population
n 5 754
% or mean 6 SD
Demographics
Age (y) 70 6 12
Gender (female) 37
Educational level




Duration of heart failure (months) e (median) 0.69
LVEF % 34 6 14








Respiratory disorders (COPD/asthma) 29
Diabetes 27
Medication burden 7.3 6 2.7








Other medication (at discharge)






Other antihypertensive medication 2.5
LVEF: left ventricular ejection fraction; NYHA: New York Heart Asso-
ciation classification; COPD: chronic obstructive pulmonary disease; ACE
inhibitors: angiotensin-converting enzyme inhibitors; ARB: angiotensin re-
ceptor blocker.
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assess significant differences between relative risks of the 2
groups.13
Next, the within group risks and RR of receiving a medication
change were calculated for each of the 5 adverse effects, looking
at discontinuation or lowering of the potential causal drugs as well
as at initiation or intensification of drugs to alleviate the specific
adverse effect. The risk of a medication change was assessed in
patients for the three intervention HF care groups and for the 3 pe-
riods of data collection separately, and ratios of relative risks
(RRR) were calculated to test for differences. When no significant
differences were observed, the groups were pooled for further
analysis and the weighted mean of the RR is presented.
Finally, risks and RR were calculated for each of the different
types of medication changes (Box 1). Statistical analyses were
performed using SPSS 16.0 software (SPSS Inc, Chicago, IL).
Results
Study Population
Of the 1023 HF patients in the COACH study, 754
patients completed the checklist in the first month, and
had a follow-up of at least 2 consecutive visits with check-
lists. The mean age at baseline was 70 years and 37% were
female (Table 1). Eighty percent of the HF patients reported
1 or more comorbidities. At discharge, the majority of
patients were on diuretics, ACE inhibitors, and b-blockers.
Total Numbers of Perceived Adverse Effects and
Medication Changes
Of the 754 patients, 50% reported dizziness, 44% dry
cough, 19% nausea, 19% diarrhea, and 12% gout on the
first checklist. During the whole study period, 544 patients
reported dry cough and 512 dizziness, whereas gout was re-
ported by 156 patients (Table 2). Of the patients reporting
dry cough, 74% were on potentially related medication
(ACE inhibitors), but only in 19% of the cases this medica-
tion was subsequently changed (Table 2). This percentage
did not differ for patients reporting dry cough on 3 consec-
utive occasions. Almost all patients reporting gout, nausea,
dizziness, and diarrhea were on prescribed medication that
could cause such effects. Those who experienced dizziness
showed the highest number of potentially related medica-
tion changes (45%). More medication changes were ob-
served in patients reporting dizziness on 3 consecutive
occasions. This was also the case for gout, nausea, and di-
arrhea (Table 2).
Likelihood of Cardiovascular Medication Changes after
Adverse Effects
The total estimated relative risk for experiencing a med-
ication change after perceiving a possible adverse effect
was 1.38 (CI 1.11-1.71). There was no significant differ-
ence between the relative risks (RRR 0.96, P 5 .3) for
changing HF-specific medication (RR 1.31, CI 1.11-1.55)
and other cardiovascular medication (RR 1.36, CI 0.90-
2.05). Also, no significant differences were found between
the care as usual group I and the intervention care groups;
basic support group II and intensive support group III (RRgroup I: 1.52, CI 0.95-2.43; group II: 1.11, CI 0.81-1.52;
group III: 1.52, CI 1.07-2.15; RRR I vs. II: 1.37, P 5 .3;
RRR I vs. III: 1.0 P 5 1.0; RRR II vs. III: 0.73, P 5
0.2), nor between the 3 periods of data collection (RR pe-
riod 1: 1.38, CI 1.11-1.71; period 2: 1.26, CI 1.00-1.58; pe-
riod 3: 1.62, CI 1.21-2.17, RRR 1 vs. 2: 1.10, P 5 .6; RRR
1 vs. 3: 0.85, P 5 .4; RRR 2 vs. 3: 0.78, P 5 .2). Conse-
quently, the groups as well as the periods were pooled to-
gether for all further analyses, and the weighted mean of
the RR is presented. The RR per period is presented in
Appendices 2 and 3 (see Appendix 2 available on page
141.e2 and Appendix 3 available on page 141.e2 at
www.onlinejcf.com).
The risk of a related medication change was significantly
increased after perceiving dry cough, nausea, dizziness, or
diarrhea with dry cough showing the highest increase in
risk of 83% (RR 5 1.83, CI 1.35-2.49) (Table 3). In case
of gout, no significant increase in cardiovascular medica-
tion changes was observed.
Table 2. Total Numbers and Percentages of Perceived Adverse Effects (AE), Related Medication, and Medication Changes after the





Total % of Related
Medication for
Reported AE
Total % of Possible Related
Medication Changes after
Reported AE
Total % of Possible Related
Medication Changes after 3
Reports of Same AE
Dry Cough 544 400/544 (74%) 77/400 (19%) 16/84 (19%)
Gout 156 150/156 (96%) 37/150 (25%) 19/41 (46%)
Nausea 259 254/259 (98%) 92/254 (36%) 21/27 (78%)
Dizziness 512 512/512 (100%) 231/512 (45%) 129/165 (78%)
Diarrhea 254 244/254 (96%) 74/244 (30%) 13/29 (45%)
*Total number of reported AE by unique patients during the whole study period.
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after Adverse Effects
Patients perceiving gout had a significant 4-fold higher
likelihood of having alleviating medication started or inten-
sified (RR 5 4.23, CI 2.23-8.05) (Table 4). For none of the
other adverse effects, increased rates of related alleviating
medication changes were observed in the follow-up period.
Type of Medication Changes
Figure 1 gives an overview of the relative risks of the dif-
ferent types of medication changes per adverse effect.
When dry cough is reported in the checklist, patients had
a significant 10-fold increased likelihood of having their
ACE inhibitor switched to an ARB (RR 5 10.67, CI 3.2-
35.55). Patients perceiving gout had a 3-fold higher likeli-
hood that their diuretics were temporarily discontinued
and reinitiated at a lower dosage (RR 5 3.32, CI 1.09-
10.04). For nausea, dizziness, and diarrhea, more diverse
types of medication changes were observed, including med-
ication discontinuations and dose decreases.
Discussion
This is the first study that looked at actual medication
changes among HF patients who perceived possible adverse
effects of their cardiovascular drugs. A considerable num-
ber of patients experienced adverse effects, with dry cough
and dizziness being common problems. The vast majority
(74% to 100%) of these patients received medication
known to cause the perceived problems. The likelihoodTable 3. Within Risks and Relative Risks for Medication Changes
Adverse Effe
AE





Dry cough 400/610 (77/400) 0
Gout 150/1617 (37/150) 0
Nausea 254/1521 (92/254) 0
Dizziness 512/811 (231/512) 0
Diarrhea 244/1468 (74/244) 0
*Relative risk is not equal to the deviation of within risk with AE and withinthat this medication was subsequently changed was 38%
higher than when no such adverse effects were reported,
but was not significantly different for HF-specific medica-
tion and other cardiovascular medication. This suggests
that, although patients are attending a HF clinic, clinicians
are not more prone to focus only on HF-specific medica-
tion.
The high number of patients experiencing adverse effects,
such as dry cough and dizziness, are in agreement with other
studies on symptom prevalence in HF.14,15 The overall likeli-
hood of medication being subsequently changed in our study
seems low in comparison to other patient populations; for ex-
ample, primary care patients of 18 years and older reported
more than 75% of medication changes in response to per-
ceived medication symptoms.16 The lower rates observed
in our population of HF patients can be attributed to multiple
underlying factors. First, patients may have failed to report
the perceived problem to their health care provider. Previous
research showed that one third to one half of patients do not
spontaneously communicate perceived adverse effects with
their physician.3,17 Patients’ involvement and willingness
to discuss and communicate health problems is influenced
by many factors. The health care setting can play a role,
where patients may perceive more difficulties in communi-
cating with hospital staff in comparison with their general
practitioner.18 The professional role of health care staff can
also affect the patients’ willingness to discuss certain com-
plaints. It was found, for example, that physical complaints
were more often communicated to the general practitioner
than to the nurse practitioner.19 Patient-related factors are
also important, where elderly patientsmay consider observedof Related Cardiovascular Drugs after Perceiving a Specific
ct (AE)




.19 (64/610) 0.10 1.83 (1.35-2.49)
.25 (322/1617) 0.20 1.24 (0.92-1.67)
.36 (364/1521) 0.24 1.51 (1.26-1.82)
.45 (270/811) 0.33 1.36 (1.18-1.55)
.30 (285/1468) 0.19 1.56 (1.26-1.94)
risk without AE because of rounding.








Changes without AE Relative Risk* (95% CI)
Dry cough 544/835 7/544 0.01 6/835 0.007 1.79 (0.61-5.30)
Gout 156/1761 12/156 0.08 32/1761 0.02 4.23 (2.23-8.05)
Nausea 259/1538 7/259 0.03 37/1538 0.02 1.12 (0.51-2.49)
Dizziness 512/811 0/512 d 0/811 d d
Diarrhea 254/1532 0/254 d 0/1532 d d
*Relative risk is not equal to the deviation of within risk with AE and within risk without AE because of rounding.
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Second, when problems are reported by patients, health
care providers may fail to acknowledge the adverse effects
or focus mainly on adverse effects which are clinically rele-
vant and necessitate immediate intervention.20,21 A study on
doctors’ attitudes revealed that up to 20% of the respondents
did not consider medication adverse effects a concern related
to clinical practice.22 During encounters on medication, pa-
tients were usually the ones who raised concerns about med-
ication problems such as adverse effects.4,23 Third, not all
perceived problems will actually be caused by related drugs,
and patients may misinterpret HF-related symptoms as ad-
verse effects ofmedication.24 Althoughwe separated general
coughing from dry cough by not including coughing reports
in the analyses, it is still possible that some patients may have
reported dry cough that was caused by fluid retention instead
of ACE inhibitor use. Finally, the low likelihood of medica-
tion being changed can partly be explained by a conscious
choice not to change the medication. Continuation of medi-
cation despite perceiving an adverse effect does not necessar-
ily indicate suboptimal quality of care but can be the result of
shared decision-making.25 After the perceived adverse effect
is discussed with the health care professional, patients may
decide to accept the adverse effect because the harm does
not weigh up against the advantages of the drugs.
Dealing with problems such as dry cough or gout may be
more straightforward in comparison to nausea, dizziness, or
diarrhea. Nausea and dizziness in particular are symptoms
that are difficult to interpret in terms of adverse effects.
They occur quite often but can be the result of many med-
ications as well as other factors, such as the disease itself or
other related diseases. This complexity may be a barrier to
change the medication. At the same time, the high number
of medications that can be related to the adverse effect will
increase the probability of observing unrelated medication
changes. This can be confirmed by our findings showing
that nausea and dizziness both had rather low relative risks
of related cardiovascular medication changes, despite hav-
ing the highest absolute numbers of medication changes.
Perceiving dry cough, on the other hand, showed a high rel-
ative risk for subsequent switches of the ACE inhibitor
medication to an ARB. This is in agreement with a survey
study among patients with hypertension showing that cough
is an adverse effect often mentioned as reason for changing
the related treatment.26 In our study, gout showed nosignificant increased overall cardiovascular medication
changes, but we did observe an increased likelihood of
a temporary discontinuation followed by a dose decrease
of the related diuretic medication. Also, we observed a large
increase in the use of alleviating drugs for gout. Both can be
considered adequate actions. Diuretics are first-line drugs in
symptomatic HF treatment, and form an essential corner-
stone of the drug therapy.1 Permanent discontinuation will
seldom be the preferred option but rather alleviating the
gout will be attempted. Alleviating symptoms would also
be an indicated response to the other adverse effects, but
we did not observe this in our study. The drugs, however,
used for alleviating these other adverse effects are mostly
over-the-counter drugs in the Netherlands, and may there-
fore not be well-documented in the patients’ charts.
Our study relies on patients’ self-reported data using
questionnaires with problem checklists that were linked to
records of actual medication changes. We focused on 5 pos-
sible drug-related adverse effects. We limited the analyses
to changes in related medication in the period after a report
of a possible adverse effect. We cannot, however, be certain
that the reported problems could indeed be attributed to the
medication, and that this was acknowledged by the health
care provider. By focusing on specific medication changes
to stop or alleviate adverse effects, we did not take all pos-
sible adequate actions into account that a health care pro-
vider might have taken in view of more full knowledge
about the (history of the) patient. On the other hand, be-
cause of recall bias, patients may not have reported all per-
ceived problems in the questionnaires. Therefore, we may
have missed some related medication changes.
A strong point of our study is that we comparedmedication
changes in patients using similar medication with or without
perceiving a related problem. This reduces the risk of attribut-
ing unrelated medication changes, for example, those caused
by efficacy problems, to the perceived adverse effect.26
Future research on this topic is needed, including a broader
range of possible adverse effects of medication, and a more
detailed documentation of other factors such as comedica-
tions and comorbidities. For practice but also for research
and monitoring purposes, it is important that the discussion
or rationales of (not) changing medication in the context of
possible adverse effects is consistently documented in pa-
tients’ charts. This is especially important for patients who
are treated by several health care providers over time.
Fig. 1. An overview of the relative risks of the different types of medication changes per adverse effect.
140 Journal of Cardiac Failure Vol. 16 No. 2 February 2010In conclusion, this study reveals a rather low likelihood
of medication being changed after patients perceived possi-
ble adverse effects of their medication. Given the high num-
ber of patients perceiving such problems, which are known
to affect quality of life and medication adherence,5 there is
a need for better management. This management shouldfocus on the factors that may underlie the apparent lack
of reaction, including the failure of acknowledging and dis-
cussing possible adverse effects by both patient and health
care professional. Patients preferred to be informed and
coached regarding adverse effects of medication.27 Health
care professionals should always consider the possibility
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of adverse effects in the differential diagnosis of perceived
symptoms in elderly patients.28 Because patients may not
know that the problems are adverse effects that might be al-
leviated by medication changes, health care professionals
should actively elicit perceived adverse effects on a recur-
rent basis.
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Included MedicationsAdverse Effect ATC Code Pharmacological Subgroup
Dry cough
Cardiovascular drugs C09A ACE inhibitors, plain
C09B ACE inhibitors, combinations
Alleviating drugs R05C Expectorants, excluding combinations with cough suppressants
R05D Cough suppressants, excluding combinations with expectorants
Gout
Cardiovascular drugs C03A Low-ceiling diuretics, thiazides
C03B Low-ceiling diuretics, excluding thiazides
C03C High-ceiling diuretics
C03E Diuretics and potassium-sparing agents in combinations
C09B ACE inhibitors, combinations
C09D Angiotensin II antagonists, combinations
Alleviating drugs M01A Antiinflammatory and antirheumatic products, nonsteroids
M04A Antigout preparations
Dizziness
Cardiovascular drugs C01A Cardiac glycosides
C01B Antiarrhythmics, class I and III
C01D Vasodilators (used in cardiac diseases)
C02A Antiadrenergic agents, centrally acting
C02C Antiadrenergic agents, peripherally acting
C02D Agents acting on arteriolar smooth muscle
C03A Low-ceiling diuretics, thiazides
C03B Low-ceiling diuretics, excluding thiazides
C03C High-ceiling diuretics
C03E Diuretics and potassium-sparing agents in combinations
C04A Peripheral vasodilators
C07A b-blocking agents
C08C Selective calcium channel blockers (vascular effects)
C08D Selective calcium channel blockers (cardiac effects)
C09A/B/C/D Agents acting on the renin-angiotensin system (excluding C09X)
Alleviating drugs N07C Antivertigo preparations
Nausea
Cardiovascular drugs C01A/B/C/D Cardiac therapy (excluding C01E)
C02A Antiadrenergic agents, centrally acting
C02C Antiadrenergic agents, peripherally acting
C03D Potassium-sparing agents
C03E Diuretics and potassium-sparing agents in combinations
C04A Peripheral vasodilators
C08C Selective calcium channel blockers (vascular effects)
C08D Selective calcium channel blockers (cardiac effects)
C09A/B/C/D Agents acting on the renin-angiotensin system (excluding C09X)
C10A Lipid modifying agents, plain
Alleviating drugs A03F Propulsives
H02A Corticosteroids for systemic use/oral use




Cardiovascular drugs C01A Cardiac glycosides
C03D Potassium-sparing agents
C03E Diuretics and potassium-sparing agents in combinations
C9A/B/C/D Agents acting on the renin-angiotensin system (excluding C09X)
Alleviating drugs A07D Antipropulsives
ACE: angiotensin-converting enzyme.
Appendix 2
Table 3bis. Within Risks and Relative Risks for Medication Changes of Related Cardiovascular Drugs after
Perceiving a Speciﬁc Adverse Effect (AE) per Period
Within Risk Within Risk
AE
Total n (with AE and on
medication/without







Dry cough: Total 400/610 77/400 64/610 1.83 (1.35-2.49)
Period 1 243/312 51/243 41/312 1.60 (1.10-2.32)
Period 2 112/180 23/112 13/180 2.84 (1.50-5.38)
Period 3 45/118 3/45 10/118 0.79 (0.23-2.73)
Gout: Total 150/1617 37/150 322/1617 1.24 (0.92-1.67)
Period 1 85/620 19/85 153/620 0.91 (0.60-1.38)
Period 2 37/544 10/37 109/544 1.35 (0.77-2.35)
Period 3 28/453 8/28 60/453 2.16 (1.15-4.10)
Nausea: Total 254/1521 92/254 364/1521 1.51 (1.26-1.82)
Period 1 143/604 65/143 191/604 1.44 (1.16-1.78)
Period 2 66/505 18/66 108/505 1.28 (0.83-1.96)
Period 3 45/412 9/45 65/412 1.27 (0.68-2.37)
Dizziness: Total 512/811 231/512 270/811 1.36 (1.18-1.55)
Period 1 379/375 185/379 149/375 1.23 (1.05-1.44)
Period 2 96/254 36/96 87/254 1.09 (0.80-1.49)
Period 3 37/182 10/37 34/182 1.45 (0.79-2.66)
Diarrhea: Total 244/1468 74/244 285/1468 1.56 (1.26-1.94)
Period 1 135/593 46/135 154/593 1.31 (1.00-1.72)
Period 2 70/483 16/70 77/483 1.43 (0.89-2.31)
Period 3 39/392 12/39 54/392 2.23 (1.31-3.80)
*Relative risk is not equal to the deviation of within risk with AE and within risk without AE because of rounding.
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Table 4bis. Within Risks and Relative Risks for Medication Changes of Alleviated Drugs after Perceiving
a Speciﬁc Adverse Effect (AE) per Per










Dry cough: Total 544/835 7/544 6/835 1.79 (0.61-5.30)
Period 1 335/419 5/335 4/419 1.56 (0.42-5.78)
Period 2 143/256 1/143 1/256 1.79 (0.11-28.41)
Period 3 66/160 1/66 1/160 2.42 (0.15-38.19)
Gout: Total 156/1761 12/156 32/1761 4.23 (2.23-8.05)
Period 1 88/666 6/88 13/666 3.49 (1.36-8.96)
Period 2 39/594 1/39 13/594 1.17 (1.16-8.73)
Period 3 29/501 5/29 6/501 14.39 (4.67-44.40)
Nausea: Total 259/1538 7/259 37/1538 1.12 (0.61-2.49)
Period 1 146/608 5/146 14/608 1.49 (0.54-4.06)
Period 2 67/513 2/67 18/513 0.85 (0.20-3.59)
Period 3 46/417 0/46 5/417 d
Dizziness: Total 512/811 0/512 0/811 d
Period 1 379/375 0/379 0/375 d
Period 2 96/254 0/96 0/254 d
Period 3 37/182 0/37 0/182 d
Diarrhea: Total 254/1532 0/254 0/1532 d
Period 1 142/612 0/142 0/612 d
Period 2 73/509 0/73 0/509 d
Period 3 39/411 0/39 0/411 d
*Relative risk is not equal to the deviation of within risk with AE and within risk without AE because of rounding.
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